Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director · 10% owner | June 02, 2026 | June 04, 2026 |
| MIMEDX GROUP, INC.MDXG · Entity 5271 | Director · 10% owner | July 02, 2020 | August 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 117,523 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 117,523 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 13,021,324 |
Reported balance
Holding disclosure · report date 2026-06-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,021,324 F1: Includes 12,096,702 shares of Class A Common Stock held by EW Healthcare Partners Acquisition Fund, L.P. ("Essex Stockholder") and 924,622 shares of Class A Common Stock held by White Pine Medical, LLC ("White Pine"). EW Healthcare Partners Acquisition Fund UGP, LLC ("General Partner") is the general partner of EW Healthcare Partners Acquisition Fund GP, L.P., which is the general partner of Essex Stockholder, which is the managing member of White Pine. Messrs. Sutter, Vainio, Eastman, and Barry (collectively, the "Managers") are the managers of the General Partner. The Managers disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 12,096,702 shares of Class A Common Stock held by EW Healthcare Partners Acquisition Fund, L.P. ("Essex Stockholder") and 924,622 shares of Class A Common Stock held by White Pine Medical, LLC ("White Pine"). EW Healthcare Partners Acquisition Fund UGP, LLC ("General Partner") is the general partner of EW Healthcare Partners Acquisition Fund GP, L.P., which is the general partner of Essex Stockholder, which is the managing member of White Pine. Messrs. Sutter, Vainio, Eastman, and Barry (collectively, the "Managers") are the managers of the General Partner. The Managers disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F3: The RSUs vested on June 2, 2026.
F4: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
MIMEDX GROUP, INC.
Report date July 02, 2020 · Filed August 28, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series B Preferred Stock, par value $.001 per shareSEC Table I · non-derivative | IndirectFund | 23,376,623 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 23,376,623 F1: The Series B Convertible Preferred Stock (the "Shares") of MiMedx Group, Inc. (the "Company") reported herein were acquired by Falcon Fund 2 Holding Company, L.P., a Delaware limited partnership (the "Fund") on July 2, 2020. The Fund is managed by EW Healthcare Partners Fund 2-UGP, LLC, its general Partner ("EWHP"). EWHP, in its capacity as the investment manager of the Fund, has the power to vote and the power to direct the disposition of all Shares held by the Fund. Accordingly, EWHP may be deemed to beneficially own shares of common stock of the Company issuable upon conversion of the Shares (the "Common Stock"). The reporting person disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person's pecuniary interest therein. F2: The Fund has the right, at its option, to convert its Shares, in whole or in part, into a number of fully paid and non-assessable shares of Common Stock equal to the Purchase Price Per Share ($1,000), plus any accrued and unpaid dividends divided by $3.85 (the "Conversion Price"), provided that such conversion does not result in the Fund, together with its affiliates, holding more than 19.9% of the votes entitled to be cast at any stockholders meeting or beneficially owning in excess of 19.9% of the then-outstanding shares of Common Stock (the "Beneficial Ownership Cap"). F3: The Shares (including any accrued and unpaid dividends) will, subject to the Beneficial Ownership Cap, automatically convert into Common Stock at any time after July 2, 2023, provided that the Common Stock has traded at 200% or more of the Conversion Price for 20 out of 30 consecutive trading days and as of the close of trading on the trading day immediately prior to the date of conversion, the Common Stock has traded at 200% or more of the Conversion Price. To the extent any Shares cannot be converted due to operation of the Beneficial Ownership Cap, it shall remain outstanding and automatically convert at such time as such conversion would be permitted under the Beneficial Ownership Cap. F4: Martin P. Sutter is one of several managers of EWHP (the "Managers"). Each of the Managers may be deemed to exercise shared voting and investment power with respect to the Shares. Each of EWHP and the Managers, including Mr. Sutter who is a member of the Company's board of directors, disclaims beneficial ownership of the shares held by the Fund, except to the extent of any pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSpouse | 500 |
Reported balance
Holding disclosure · report date 2020-07-02 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 500 F5: This amendment is filed to correct a typographical error which incorrectly attributed 500 shares to the wrong director. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Convertible Preferred Stock (the "Shares") of MiMedx Group, Inc. (the "Company") reported herein were acquired by Falcon Fund 2 Holding Company, L.P., a Delaware limited partnership (the "Fund") on July 2, 2020. The Fund is managed by EW Healthcare Partners Fund 2-UGP, LLC, its general Partner ("EWHP"). EWHP, in its capacity as the investment manager of the Fund, has the power to vote and the power to direct the disposition of all Shares held by the Fund. Accordingly, EWHP may be deemed to beneficially own shares of common stock of the Company issuable upon conversion of the Shares (the "Common Stock"). The reporting person disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person's pecuniary interest therein.
F2: The Fund has the right, at its option, to convert its Shares, in whole or in part, into a number of fully paid and non-assessable shares of Common Stock equal to the Purchase Price Per Share ($1,000), plus any accrued and unpaid dividends divided by $3.85 (the "Conversion Price"), provided that such conversion does not result in the Fund, together with its affiliates, holding more than 19.9% of the votes entitled to be cast at any stockholders meeting or beneficially owning in excess of 19.9% of the then-outstanding shares of Common Stock (the "Beneficial Ownership Cap").
F3: The Shares (including any accrued and unpaid dividends) will, subject to the Beneficial Ownership Cap, automatically convert into Common Stock at any time after July 2, 2023, provided that the Common Stock has traded at 200% or more of the Conversion Price for 20 out of 30 consecutive trading days and as of the close of trading on the trading day immediately prior to the date of conversion, the Common Stock has traded at 200% or more of the Conversion Price. To the extent any Shares cannot be converted due to operation of the Beneficial Ownership Cap, it shall remain outstanding and automatically convert at such time as such conversion would be permitted under the Beneficial Ownership Cap.
F4: Martin P. Sutter is one of several managers of EWHP (the "Managers"). Each of the Managers may be deemed to exercise shared voting and investment power with respect to the Shares. Each of EWHP and the Managers, including Mr. Sutter who is a member of the Company's board of directors, disclaims beneficial ownership of the shares held by the Fund, except to the extent of any pecuniary interests therein.
F5: This amendment is filed to correct a typographical error which incorrectly attributed 500 shares to the wrong director.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABIOMED INC
Report date December 22, 2022 · Filed December 27, 2022
Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 1
1 source rowRow 1 · 2022-12-22 · Disposition to issuer · Disposed 123,370 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on November 17, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.
F3: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on November 17, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2018 Filed May 9, 2018 19:26 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock, $0.01 par value | 400 | $342.00 | $136,798.56 |
DisclosureSEC source: 0001179110-18-006502 · edgar.xml · nonDerivative · entry 3 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,277 F19 · kind: Transaction represents shares of common stock sold for the payment of the exercise price of stock options and withholding taxes associated with stock option exercise. F19 · shares: Transaction represents shares of common stock sold for the payment of the exercise price of stock options and withholding taxes associated with stock option exercise. F7 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $341.8400 and $342.2700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 08, 2018 Filed May 9, 2018 19:26 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock, $0.01 par value | 700 | $340.47 | $238,329.28 |
DisclosureSEC source: 0001179110-18-006502 · edgar.xml · nonDerivative · entry 2 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,677 F19 · kind: Transaction represents shares of common stock sold for the payment of the exercise price of stock options and withholding taxes associated with stock option exercise. F6 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $340.3300 and $340.5700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 08, 2018 Filed May 9, 2018 19:26 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionCommon Stock, $0.01 par value | 25,000 | $13.91 | $347,750.00 |
DisclosureSEC source: 0001179110-18-006502 · edgar.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 17:51 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 58 | $290.99 | $16,877.42 |
DisclosureSEC source: 0001179110-18-005307 · edgar.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,377 F6 · kind: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. F6 · shares: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 16:16 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 90 | $187.41 | $16,866.90 |
DisclosureSEC source: 0001179110-18-000248 · edgar.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,319 F6 · kind: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. F6 · shares: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. Read SEC document |
| September 30, 2017 Filed Oct 4, 2017 16:07 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 100 | $168.60 | $16,860.00 |
DisclosureSEC source: 0001179110-17-013093 · edgar.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,229 F6 · kind: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. F6 · shares: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 16:09 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 1,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-011392 · edgar.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,129 F6 · kind: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the later of: (a) August 9, 2018; or (b) the date of the Issuer's next annual meeting of stockholders. F6 · shares: Represents shares underlying the grant of restricted stock units that are to be settled in common stock upon vesting. The restricted stock units will vest in full on the later of: (a) August 9, 2018; or (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:37 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 117 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010105 · edgar.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,843 F6 · kind: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. F6 · shares: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. Read SEC document |
| March 31, 2017 Filed Apr 13, 2017 19:11 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005984 · edgar.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,726 F6 · kind: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. F6 · shares: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 16:16 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-000188 · edgar.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,591 F6 · kind: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. F6 · shares: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:13 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 131 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030259 · edgar.xml · nonDerivative · entry 1 SUTTER MARTIN P · CIK 0001017832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,441 F6 · kind: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. F6 · shares: This stock was issued to the Reporting Person in lieu of a retainer of $16,875 for compensation for his service as a board member of ABIOMED, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.